Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexant Key secondary endpoint, defined as Wake After Sleep Onset over first 6 hours (WASO‑6) at Night 1, showed improvement with a
View HTML
Toggle Summary Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific orexin- 2 receptor antagonist for the treatment of insomnia Key Opinion Leaders, Dr. Thomas Roth and Dr.
View HTML
Toggle Summary Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
WALTHAM, Mass. , June 12, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities
View HTML
Toggle Summary Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
WALTHAM, Mass. , May 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2019
View HTML
Toggle Summary Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
Potential first-in-class, oral specific orexin- 2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar to or lower than the rate observed in the placebo group Improves depressive symptoms and sleep
View HTML
Toggle Summary Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass. , May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter
View HTML
Toggle Summary Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
Management to host conference call WALTHAM, Mass. , April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
Toggle Summary Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM, Mass. , April 11, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
View HTML
Toggle Summary Minerva Neurosciences to Host Webcast Event on Schizophrenia
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass. , March 18, 2019 (GLOBE NEWSWIRE) -- Minerva
View HTML
Toggle Summary Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia disorder Five key data readouts expected in 2019  Management to host conference call today at 8:30 a.m.
View HTML